Back to Search Start Over

Anti-BPIFA1/SPLUNC1: a new autoantibody prevalent in patients with endstage cystic fibrosis.

Authors :
Budding K
van de Graaf EA
Hoefnagel T
Hack CE
Otten HG
Source :
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society [J Cyst Fibros] 2014 May; Vol. 13 (3), pp. 281-8. Date of Electronic Publication: 2013 Oct 23.
Publication Year :
2014

Abstract

Background: Bactericidal/permeability increasing protein fold containing family A (BPIFA) 1, is a secreted protein of the upper airways that shares structural homology with BPI and exhibits comparable antimicrobial capacities. We hypothesized that CF patients have circulating IgG or IgA anti-BPIFA1 autoantibodies, similarly as reported for BPI autoantibodies.<br />Methods: We analyzed pre- and post-transplantation sera from 67 endstage lung disease patients who underwent lung transplantation (LTx) because of COPD (n=27), CF (n=25), and ILD (n=15).<br />Results: Anti-BPIFA1 (48%) and anti-BPI (92%) were elevated in CF patients compared to healthy controls, with anti-BPIFA1 IgG isotype being most prevalent, whereas anti-BPI is of the IgA isotype. Levels of anti-BPI autoantibodies significantly declined post-LTx, whereas anti-BPIFA1 did not. No relation was found between autoantibodies against BPIFA1 and BPI.<br />Conclusion: Our results indicate that BPIFA1 is a novel target for autoantibodies in CF. The function of these autoantibodies needed to be investigated in future studies.<br /> (© 2013.)

Details

Language :
English
ISSN :
1873-5010
Volume :
13
Issue :
3
Database :
MEDLINE
Journal :
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Publication Type :
Academic Journal
Accession number :
24269518
Full Text :
https://doi.org/10.1016/j.jcf.2013.10.005